Search results
Willner & Heller LLC Purchases New Holdings in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 2 days agoWillner & Heller LLC acquired a new position in Pfizer Inc. (NYSE:PFE – Free Report) in the 4th quarter, HoldingsChannel reports. The fund acquired 19,822 shares of the biopharmaceutical ...
Pfizer study finds Paxlovid ineffective against Long COVID despite federal research funds
22 WSBT South Bend· 7 days agoLong COVID is a chronic condition resulting from an initial infective with COVID-19, according to...
Merck's vaccine approval poses threat to one of Pfizer's top-selling products
Morningstar· 1 day agoMerck & Co. Inc. on Monday gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.'s top-selling products. The Food and Drug ...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 5 days agoPfizer disclosed on May 7 that a child participating in another...
Pfizer (NYSE:PFE) Stock Price Down 0.9%
ETF DAILY NEWS· 4 days agoPfizer Inc. (NYSE:PFE – Get Free Report) was down 0.9% during trading on Thursday . The company traded as low as $27.20 and last traded at $27.41. Approximately 11,513,196 ...
Pfizer, Flagship to focus on obesity drugs under $100M collaboration - Boston Business Journal
The Business Journals· 6 days agoAlmost a year after Cambridge’s Flagship Pioneering and Pfizer Inc. announced a partnership to...
Pfizer Inc. (NYSE:PFE) Stake Boosted by Wellington Management Group LLP
ETF DAILY NEWS· 2 days agoWellington Management Group LLP lifted its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 4.9% during the 4th quarter, according to its most recent disclosure ...
Is It Too Late to Buy Pfizer Stock? | The Motley Fool
The Motley Fool· 5 days agoAre Pfizer's (PFE -0.43%) best days behind it? If the stock's critics are to be believed, the answer...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 6 days agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 5 days agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...